Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Seoul
Clinical trial register · South Korea

Clinical Trials in Seoul, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3365 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:17 UTC
3365
Studies in scope
all four open statuses
1831
Recruiting now
open to new participants
500
Lead sponsors
across recruiting studies
Top sites
Seoul 87 Busan 16 Daegu 13 Incheon 13 Suwon 13
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca195 Seoul National University Hospital183 Yonsei University143 Samsung Medical Center142 Merck Sharp & Dohme LLC111 Clear sponsor filter
Site location
Seoul87 Busan16 Daegu13 Incheon13 Suwon13
All 41 locations
Target enrolment
to

Trials with a site in Seoul

87 of 3365 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Recruiting
Novartis Pharmaceuticals
Phase 3
180
Ansan, Seoul
2026-08-24
Recruiting
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
NCT07498335Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy
DrugAtrasentan
Novartis Pharmaceuticals
Phase 3
28
Seoul
2026-08-06
Recruiting
Novartis Pharmaceuticals
Phase 3
570
Gwangju, Seoul
2026-07-16
Recruiting
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
NCT07564401Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Novartis Pharmaceuticals
Phase 1/2
80
Seoul
2026-06-16
Recruiting
A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy
NCT07416162Paroxysmal Nocturnal Hemoglobinuria, C3 Glomerulopathy
Novartis Pharmaceuticals
Observational
21
Jeollanam, Seoul
2026-06-15
Active, closed
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
NCT07468071Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation
DrugsTNO155·Opnurasib·Trametinib·Cetuximab
Novartis Pharmaceuticals
Phase 1/2
25
Seoul
2026-06-08
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals
Phase 3
300
Seoul
2026-06-03
Recruiting
Novartis Pharmaceuticals
Phase 1
194
Seoul
2026-05-28
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
460
Suwon, Jeonju, Seoul, Busan
2026-05-27
Recruiting
Novartis Pharmaceuticals
Phase 1
208
Seoul
2026-05-25
Recruiting
Novartis Pharmaceuticals
Phase 3
5,700
Daegu, Wŏnju, Bundang Gu, Suwon, Incheon, Seoul, Busan, Gwangju
2026-05-11
Recruiting
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
NCT07354074Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
DrugsAsciminib single agent·ABL001
Novartis Pharmaceuticals
Phase 2
50
Seoul
2026-04-28
Recruiting
Remibrutinib Open Label Roll-over Post-trial Access Protocol
NCT07456891Indication of the Parent Protocol
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
648
Daegu, Hwaseong-si, Suwon, Dongjak Gu, Seoul, Gwangju, Incheon
2026-04-16
Recruiting
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
NCT07146906Immunoglobulin A Nephropathy (IgAN)
DrugZigakibart
Novartis Pharmaceuticals
Phase 2
32
Seoul
2026-03-26
Recruiting
Novartis Pharmaceuticals
Phase 3
770
Daejeon, Dongjak Gu, Seoul, Busan
2026-03-24
Recruiting
Novartis Pharmaceuticals
Phase 1/2
181
Seoul
2026-01-13
Recruiting
Novartis Pharmaceuticals
Observational
76
Seoul
2025-12-22
Recruiting
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
NCT07006727Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma
Novartis Pharmaceuticals
Phase 1
116
Seoul
2025-10-16
Recruiting
Novartis Pharmaceuticals
Phase 3
300
Seoul
2025-10-03
Recruiting
Leqvio rPMS (Regulatory Post-Marketing Surveillance in Korea)
NCT06770543Primary Hypercholesterolemia or Mixed Dyslipidemia
Novartis Pharmaceuticals
Observational
1,500
Yangsan, Busan, Seoul, Taegu
2025-08-13
Recruiting
Novartis Pharmaceuticals
Phase 2
407
Seoul, Incheon
2025-08-07
Recruiting
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
NCT06858319Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases, Glomerulonephritis
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
220
Cheonan, Guri-si, Seongnam-si, Seoul
2025-07-28
Active, closed
Novartis Pharmaceuticals
Phase 2
168
Seoul
2025-07-07
Active, closed
Novartis Pharmaceuticals
Phase 2
138
Seoul
2025-07-03
Recruiting
Novartis Pharmaceuticals
Phase 3
940
Seoul
2025-07-01
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
DrugOctreotide LAR
Novartis Pharmaceuticals
Phase 3
240
Seoul
2025-05-30
Recruiting
Novartis Pharmaceuticals
Phase 3
348
Suwon, Seoul
2025-05-19
Recruiting
Novartis Pharmaceuticals
Phase 2
224
Ansan, Seoul
2025-05-16
Recruiting
Post Marketing Study on Pluvicto in Korea
NCT06514521Metastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals
Observational
278
Seongnam-si, Suwon, Busan, Gyeonggi-do, Seoul, Jeollanam
2025-04-18
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
DrugsRibociclib·Fulvestrant
Novartis Pharmaceuticals
Phase 1/2
280
Seoul
2025-04-03
Recruiting
Ilaris NIS in Korea
NCT06838143Hereditary Periodic Fever Syndromes, Cryopyrin-associated Periodic Syndromes (CAPS), Colchicine Resistance Familial Mediterranean Fever (crFMF), TNF Receptor Associated Periodic Syndrome (TRAPS)
Novartis Pharmaceuticals
Observational
25
Seoul
2025-03-29
Recruiting
Long-term Follow up Local Registry Study of Kymriah in South Korea
NCT06785818B-Cell Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Novartis Pharmaceuticals
Observational
500
Bundang Gu, Seongnam-si, Gyeonggi-do, Incheon, Seoul, Busan, Jeollanam, Ulsan
2025-03-12
Recruiting
Novartis Pharmaceuticals
Phase 2/3
443
Seoul
2025-02-27
Active, closed
Novartis Pharmaceuticals
Phase 3
180
Busan, Seoul
2025-02-07
Active, closed
Novartis Pharmaceuticals
Phase 2
96
Seoul
2024-10-29
Active, closed
Novartis Pharmaceuticals
Phase 2
251
Yangsan, Seoul
2024-10-17
Recruiting
Novartis Pharmaceuticals
Phase 2
200
Seoul, Busan
2024-10-09
Active, closed
Novartis Pharmaceuticals
Phase 2
179
Seoul
2024-09-04
Active, closed
Novartis Pharmaceuticals
Phase 1/2
20
Seoul
2024-08-14
Active, closed
Novartis Pharmaceuticals
Phase 3
146
Daegu, Gwangju, Seoul
2024-07-31
Recruiting
Novartis Pharmaceuticals
Phase 3
550
Gwangju, Seoul
2024-05-21
Recruiting
Novartis Pharmaceuticals
Phase 3
1,400
Bundang Gu, Gyeonggi-do, Seoul, Incheon, Seongnam Gyeonggi
2024-02-28
Active, closed
Novartis Pharmaceuticals
Phase 2
49
Seoul
2024-01-03
Active, closed
Novartis Pharmaceuticals
Phase 3
362
Suwon, Seoul
2023-12-07
Active, closed
Novartis Pharmaceuticals
Phase 3
470
Ansan, Busan, Seoul
2023-11-15
Active, closed
Novartis Pharmaceuticals
Phase 3
612
Gwangju, Seoul
2023-10-27
Recruiting
Novartis Pharmaceuticals
Phase 3
106
Seoul
2023-10-02
Active, closed
Novartis Pharmaceuticals
Phase 3
109
Seoul
2023-10-02
Active, closed
Novartis Pharmaceuticals
Phase 2
41
Seoul
2023-08-16
Recruiting
Asciminib RMP Study
NCT05943522Chronic Myeloid Leukemia
Novartis Pharmaceuticals
Observational
600
Wŏnju, Anyang-si, Bucheon-si, Uijeongbu-si, Gyeonggi-do, Incheon, Seoul, Suwon
2023-07-19
Active, closed
Novartis Pharmaceuticals
Phase 1
123
Seoul
2023-06-27
Recruiting
Novartis Pharmaceuticals
Observational
44
Daegu, Suwon, Incheon, Seoul, Busan, Daejeon, Jeollanam
2023-06-12
Active, closed
Novartis Pharmaceuticals
Phase 3
288
Gwangju Gwangyeoksi, Seoul
2023-04-21
Active, closed
Novartis Pharmaceuticals
Phase 3
152
Jeollanam, Seoul
2023-02-02
Active, closed
Novartis Pharmaceuticals
Phase 3
696
Daegu, Hwaseong-si, Suwon, Incheon, Seoul, Gwangju
2022-12-09
Active, closed
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
NCT05544929Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
DrugsKeytruda·Pembrolizumab
Novartis Pharmaceuticals
Phase 1
126
Seoul
2022-10-26
Active, closed
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT05358249KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
DrugsOpnurasib·Trametinib·Ribociclib·Cetuximab
Novartis Pharmaceuticals
Phase 1/2
74
Seoul
2022-10-24
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 4
347
Uijeongbu-si, Busan, Jeollanam, Seoul
2022-08-30
Active, closed
Novartis Pharmaceuticals
Phase 3
452
Bundang Gu, Suwon, Gwangju, Seoul
2022-07-14
Active, closed
Novartis Pharmaceuticals
Phase 1/2
55
Seoul
2022-07-13
Active, closed
Novartis Pharmaceuticals
Phase 3
610
Bundang Gu, Goyang-si, Seoul
2022-07-08
Active, closed
Novartis Pharmaceuticals
Phase 4
134
Seoul
2022-07-07
Recruiting
Novartis Pharmaceuticals
Observational
900
Cheonan Si, Daegu, Goyang-si, Suwon, Gyeonggi-do, Seoul, Busan, Daejeon
2022-06-29
Recruiting
Novartis Pharmaceuticals
Phase 1/2
34
Seoul
2021-12-27
Active, closed
Novartis Pharmaceuticals
Phase 3
17,004
Daegu, Wŏnju, Bundang Gu, Jinju, Yangsan, Incheon, Seoul, Cheongju-si
2021-11-23
Active, closed
Novartis Pharmaceuticals
Phase 3
153
Seoul
2021-11-15
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
DrugsBosutinib·Asciminib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 3
405
Uijeongbu-si, Seoul
2021-10-06
Recruiting
Novartis Pharmaceuticals
Phase 3
540
Bundang Gu, Seoul, Cheongju-si, Busan, Taegu
2021-09-20
Active, closed
Novartis Pharmaceuticals
Phase 3
208
Seoul
2021-07-27
Active, closed
Novartis Pharmaceuticals
Phase 3
1,140
Seoul
2021-06-09
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
430
Jinju, Busan, Daegu, Gyeonggi-do, Incheon, Jeonju, Seoul, Ulsan
2021-04-09
Active, closed
Atrasentan in Patients With Proteinuric Glomerular Diseases
NCT04573920IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease
DrugAtrasentan
Novartis Pharmaceuticals
Phase 2
103
Cheonan, Anyang-si, Seoul
2021-03-15
Active, closed
Novartis Pharmaceuticals
Phase 3
345
Wŏnju, Incheon, Seoul, Gwangju
2021-03-01
Active, closed
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
DrugsTNO155·Opnurasib·Tislelizumab
Novartis Pharmaceuticals
Phase 1/2
344
Seoul
2021-02-24
Recruiting
Secukinumab Open Label Roll-over Extension Protocol
NCT04638647Autoimmunity, Inflammation
DrugSecukinumab
Novartis Pharmaceuticals
Phase 4
1,000
Seoul
2020-12-22
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
DrugsAtrasentan·Zigakibart
Novartis Pharmaceuticals
Phase 3
404
Anyang, Daejeon, Gyeonggi-do, Jeju City, Seongnam-si, Seoul
2020-12-11
Active, closed
Novartis Pharmaceuticals
Phase 1
120
Seoul
2019-10-30
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
DrugsTulmimetostat·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
300
Daegu, Goyang-si, Incheon, Seoul
2019-09-18
Active, closed
Novartis Pharmaceuticals
Phase 2
22
Seoul
2019-03-13
Active, closed
Novartis Pharmaceuticals
Phase 3
5,101
Seoul, Wŏnju, Bundang Gu, Suwon, Gyeonggi-do, Cheongju-si, Incheon, Seongnam Gyeonggi
2018-12-07
Recruiting
Novartis Pharmaceuticals
Observational
700
Daegu, Seongnam-si, Seoul, Yangsan, Yongin-si
2018-09-25
Active, closed
Novartis Pharmaceuticals
Phase 3
206
Seoul
2017-08-23
Active, closed
Novartis Pharmaceuticals
Phase 2
29
Seoul
2017-07-04
Active, closed
Novartis Pharmaceuticals
Phase 4
233
Seoul
2015-12-11
Recruiting
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals
Phase 3
1,105
Seoul
2015-11-02
Active, closed
CINC424A2X01B Rollover Protocol
NCT02386800Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia
DrugsPanobinostat·Jakavi·Ruxolitinib
Novartis Pharmaceuticals
Phase 4
279
Seoul
2015-03-05
Active, closed
Novartis Pharmaceuticals
Phase 1/2
259
Seoul
2013-10-22
Rows per page Showing 1–87 of 87
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-south-korea/city/seoul

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,365 studies in total at the last sync on 11 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 87 of those studies with a site in Seoul that also match the filters currently applied.

How many clinical trials are recruiting in Seoul?

44 of the 87 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:17 UTC sync. A further 0 have not yet opened recruitment, 43 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Seoul), 87 studies
PhaseStudiesRecruitingShare
Phase 3391844.8%
Phase 215517.2%
Phase 1/211512.6%
Observational101011.5%
Phase 1636.9%
Phase 4525.7%
Phase 2/3111.1%

Most active sponsors

Lead sponsors with the most studies (Seoul)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals8744
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.